Free shipping on all orders over $ 500

PLX5622

Cat. No. M9512
PLX5622 Structure
Synonym:

PLX5622 free base; PLX-5622

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 40  USD40 In stock
5mg USD 90  USD90 In stock
10mg USD 150  USD150 In stock
50mg USD 440  USD440 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor with an Ki of 5.9 nM. PLX5622 eliminates microglia from the brain, which can be sustained in wild-type and the Alzheimer's disease model mice (3xTg-AD model). In the AD model PLX5622 prevents microglial association with amyloid β plaques and improves cognition.

In vivo, PLX5622 (65 mg/kg/day; oral gavage for 14 days) causes paw withdrawal threshold high in mice, indicating that PLX5622 prevents the development of injury-associated mechanical allodynia.

Chemical Information
Molecular Weight 395.41
Formula C21H19F2N5O
CAS Number 1303420-67-8
Solubility (25°C) DMSO ≥ 65 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Spangenberg E, et al. Nat Commun. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.

[2] Yiting Liu, et al. Exp Neurol . Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo

[3] Lee S, et al. Mol Pain. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain.

Related CSF-1R (c-Fms) Products
Tinengotinib

Tinengotinib is a modulator of several protein kinases, such as Aurora kinase, VEGFR kinase, and CSF-1R, etc. Tinengotinib can be used in studies related to diseases mediated by abnormalities in these kinases.

AMG-820

AMG-820 is an anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody.

CSF1R-IN-15

CSF1R-IN-15 is an inhibitor targeting CSF1R.

Pimicotinib

Pimicotinib is a novel, orally bioavailable, highly selective small-molecule inhibitor of colony-stimulating factor 1 (CSF-1) with antitumor activity and less inhibitory effects on c-Kit and PDGFR.

c-Fms-IN-14

c-Fms-IN-14 is a c-Fms inhibitor with an IC50 value of 4 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: PLX5622, PLX5622 free base; PLX-5622 supplier, CSF-1R (c-Fms), inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.